{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.","id":"OG000","title":"SF1126"}],"reportingStatus":"POSTED","timeFrame":"4 years","title":"To Assess Disease-related Patient-reported Outcomes Using the EORTC-QLQ-","type":"SECONDARY"}